Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610808 | 0.96 | CYP17A1 (0.49) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL25975052 | 0.86 | CYP17A1 (0.43) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL9893568 | 0.84 | HDAC3 (0.42) | CYP17A1NAMPTCA12CA1CA9 | |
| SCHEMBL1016475 | 0.84 | SMN1; SMN2 (0.45) | NAMPTCA12CA1CA9TRPV1 | |
| SCHEMBL3348070 | 0.83 | KIF11 (0.45) | TRPV1 | |
| SCHEMBL2787414 | 0.82 | TRPV1 (0.53) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL12869625 | 0.82 | CYP17A1 (0.47) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL2370528 | 0.82 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL595748 | 0.81 | GSK3B (0.40) | CYP17A1PSMB8NAMPTMAPKAPK2 | |
| SCHEMBL59499 | 0.81 | TRPV1 (0.57) | CYP17A1PSMB8NAMPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-2513113-B1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075615-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010120994-A2 | UREIDOARYL-AND CARBAMOYLARYL-MORPHOLINO- PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | SCN1A, SCN3A, SCN1B | CYP17A1 2256/4885PSMB8 4069/4885NAMPT 362/4885 |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | CYP17A1 159/4885PSMB8 553/4885NAMPT 2823/4885 |
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | CYP17A1 225/4885PSMB8 3801/4885NAMPT 990/4885 |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP17A1 906/4885PSMB8 3370/4885NAMPT 1606/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CYP17A1 3531/4885PSMB8 4156/4885NAMPT 3414/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP17A1 906/4885PSMB8 3370/4885NAMPT 1606/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP17A1 906/4885PSMB8 3370/4885NAMPT 1606/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP17A1 906/4885PSMB8 3370/4885NAMPT 1606/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | CYP17A1 906/4885PSMB8 3370/4885NAMPT 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.